Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings

Title: Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings

Volume: 16 Issue: 18

Author(s): D.J. Veltman, H.G. Ruhe and J. Booij

Affiliation:

Keywords: Serotonin, positron emission tomography, depression, schizophrenia, Alzheimer, epilepsy

Abstract: Mono-aminergic neurotransmitters, in particular serotonin (5-HT), are involved in regulating a large number of psychological and physiological functions, and abnormal 5-HT transmission has been implicated in a wide variety of neuropsychiatric disorders. Positron emission tomography (PET) is a non-invasive nuclear imaging technique with exquisite sensitivity and specificity, allowing delineation of neurotransmitter function in vivo. Over the last two decades, PET has been used to investigate 5-HT function in several neuropsychiatric disorders, in particular mood and anxiety disorders, schizophrenia, Alzheimers disease, and impulse control disorders. In the present review, an overview of recent findings is provided, and possibilities for further research are discussed.

Cite this article as:

Veltman D.J., Ruhe H.G. and Booij J., Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings, Current Pharmaceutical Design 2010; 16(18) . https://dx.doi.org/10.2174/138161210791293033